Verona Pharma (UK) ((GB:VRP)), Verona Pharma ((VRNA)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Verona Pharma is conducting a Phase II study titled ‘A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease.’ The study aims to evaluate the pharmacokinetics and safety of a fixed-dose combination of ensifentrine and glycopyrrolate compared to each drug alone in individuals with COPD.
The study tests a combination of drugs, including Ensifentrine and Glycopyrrolate, administered via inhalation. Ensifentrine is tested in different formulations and doses to determine its efficacy and safety.
This interventional study is randomized and employs a crossover design with triple masking, involving participants, investigators, and outcomes assessors. The primary purpose is treatment-focused, aiming to gather comprehensive data on the drugs’ effects.
The study is set to start on September 30, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on August 19, 2025, indicating the study is in the preparatory phase.
The study’s progress could impact Verona Pharma’s stock performance, as positive results may enhance investor confidence. The COPD treatment market is competitive, and advancements in drug efficacy can influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.